Adolescents in a long-term, open-label extension study receiving a twice-daily low dose of repinatrabit achieved clinically meaningful reductions in blood Phe levels at month one of the open-label ...
Thank you for standing by. My name is Tina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Atai Beckley BPL-003 phase IIb open-label extension ...
The last time I spoke about Greenwich LifeSciences (GLSI), it was with respect to a Seeking Alpha article entitled "Greenwich LifeSciences: Halting Of Breast Cancer Recurrence With GLSI-100." With ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results